Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Accumulated Depreciation (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Accumulated Depreciation for 7 consecutive years, with $15.6 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation rose 9.75% to $15.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.6 million through Dec 2025, up 9.75% year-over-year, with the annual reading at $15.6 million for FY2025, 9.75% up from the prior year.
  • Accumulated Depreciation for Q4 2025 was $15.6 million at Fulcrum Therapeutics, up from $15.3 million in the prior quarter.
  • The five-year high for Accumulated Depreciation was $15.6 million in Q4 2025, with the low at $6.7 million in Q1 2021.
  • Average Accumulated Depreciation over 5 years is $11.6 million, with a median of $12.1 million recorded in 2023.
  • The sharpest move saw Accumulated Depreciation surged 54.83% in 2021, then rose 9.75% in 2025.
  • Over 5 years, Accumulated Depreciation stood at $8.3 million in 2021, then rose by 28.94% to $10.7 million in 2022, then grew by 19.68% to $12.8 million in 2023, then increased by 11.73% to $14.3 million in 2024, then grew by 9.75% to $15.6 million in 2025.
  • According to Business Quant data, Accumulated Depreciation over the past three periods came in at $15.6 million, $15.3 million, and $15.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.